|
Market Closed -
Nasdaq
00:30:00 16/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 1.957 USD | +4.08% |
|
-5.01% | -32.06% |
Company Valuation: Processa Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 69.68 | 77.01 | 17.59 | 8.242 | 2.887 | 6.525 |
| Change | - | 10.51% | -77.16% | -53.15% | -64.97% | 126% |
| Enterprise Value (EV) 1 | 54.59 | 60.59 | 11.32 | 3.686 | 1.769 | 0.9885 |
| Change | - | 10.98% | -81.32% | -67.43% | -51.99% | -44.14% |
| P/E | -2.6x | -6.57x | -0.65x | -0.79x | -0.23x | -0.28x |
| PBR | 4.08x | 3.02x | 2.36x | 1.72x | 1.93x | 1.33x |
| PEG | - | 0.1x | -0x | 0x | 0x | 0x |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -9.69x | -5.62x | -0.58x | -0.32x | -0.15x | -0.07x |
| EV / EBIT | -8.48x | -5.24x | -0.56x | -0.32x | -0.15x | -0.07x |
| EV / FCF | -237x | -14.5x | -3.82x | -0.9x | -0.3x | -0.15x |
| FCF Yield | -0.42% | -6.92% | -26.2% | -111% | -331% | -663% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -1,269 | -373 | -851.2 | -212 | -96.82 | -10.36 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -5.633 | -10.78 | -19.47 | -11.46 | -12.05 | -13.99 |
| EBIT 1 | -6.437 | -11.57 | -20.26 | -11.46 | -12.05 | -13.99 |
| Net income 1 | -14.41 | -11.43 | -27.42 | -11.12 | -11.85 | -13.56 |
| Net Debt 1 | -15.09 | -16.42 | -6.274 | -4.556 | -1.118 | -5.537 |
| Reference price 2 | 3,297.500 | 2,450.000 | 550.000 | 167.300 | 22.095 | 2.880 |
| Nbr of stocks (in thousands) | 21.1 | 31.4 | 32 | 49.3 | 131 | 2,266 |
| Announcement Date | 25/03/21 | 30/03/22 | 30/03/23 | 29/03/24 | 20/03/25 | 18/03/26 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 5.25M | |
| 20.63x | 7.28x | 14.62x | 1.44% | 70.24B | |
| 32.28x | 9.34x | 45.05x | 0.04% | 62.63B | |
| -76.7x | 14.8x | -71.37x | -.--% | 27.36B | |
| 29.77x | 6.32x | 16.41x | -.--% | 25.71B | |
| -15.03x | 5.62x | -7.06x | -.--% | 24.83B | |
| 26.45x | 5.03x | 16.73x | -.--% | 19.52B | |
| 44.88x | 16.47x | 33.42x | 0.34% | 15.51B | |
| 1267.62x | 36.68x | 797.93x | -.--% | 14.66B | |
| -15.8x | 3569.89x | -18.25x | -.--% | 14.69B | |
| Average | 146.01x | 407.94x | 91.94x | 0.2% | 27.52B | |
| Weighted average by Cap. | 77.53x | 200.44x | 52.40x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PCSA Stock
- Valuation Processa Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
